阻抑蛋白在肝硬化和原发性肝癌组织中的表达及意义

Expression and significance of prohibitin in liver cirrhosis and primary hepatic carcinoma

目的探讨阻抑蛋白在肝硬化和原发性肝癌(肝癌)组织中的表达及临床病理学意义。方法采用免疫组织化学EnVision法检测阻抑蛋白在32例肝癌组织、19例肝硬化组织和21例对照肝组织标本中的表达,并分析其与临床病理参数的相关性。结果肝癌组阻抑蛋白阳性表达率为100%,高于肝硬化组的78.95%和对照组的80.95%(P<0.05);肝癌组织中阻抑蛋白的表达与患者的性别、年龄、肿瘤大小、肿瘤数目、肿瘤有无坏死、门静脉有无癌栓、肿瘤分化程度、肿瘤的临床分期和TNM分期均无关(P>0.05)。结论阻抑蛋白参与了肝癌的发生发展过程,对于小肝癌的诊断可能具有一定的临床应用价值。

Objective To investigate the expression and significance of prohibitin in liver cirrhosis and primary hepatic carcinoma（PHC）. Methods The prohibitin expression was detected by EnVision immunohistochemistry in 19 liver cirrhosis specimens, 32 PHC specimens and 21 control ones（ll tumor-adjacent non-cirrhotic specimens, 4 hemangiomas and 6 calculus of intrahepatic duct）. The correlation of prohibitin expression with clinical and pathological characteristics of PHC was analyzed as well. Results The positive rate of prohibitin was 100%in PHC tissues, which was higher than 78. 95% in hepatic cirrhosis tissues and 80. 95% in control group（P〈0. 05）. The expression of prohibitin in PHC tissues was not significantly related to the gender, age, tumor size, tumor number, necrosis, portal vein cancer embolus, differentiation degree, clinical staging and TNM staging （P〈0. 05）. Conclusion Prohibitin is involved in the progression of PHC and might have a potential clinical value in the diagnosis of PHC.